HUMA - Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

2024-05-14 16:02:12 ET

Summary

• Humacyte's stock price has recently been on an impressive bull run, jumping from $4.50 to $6.50 after management announced Q1 2024 earnings.
• The company's market cap valuation is currently around $765 million - I believe this could rise >$1bn if the company secures a first commercial approval this year, as is likely.
• Humacyte focuses on regenerative medicine technology, specifically bioengineered human tissues, and has a Biologics License Application accepted by the FDA for its Human Acellular Vessels.
• The opportunity is in vascular wound treatment, and the FDA has set a decision date for Aug. 10, after awarding a priority review.
• Humacyte's innovative product that uses a degradable polymer mesh to encourage cell proliferation may be an improvement on current standards of care.

Investment Overview

Durham, N.C.,-based Humacyte ( HUMA ) - a specialist in the field of regenerative medicine technology, announced its Q1 2024 earnings on May 10, triggering an impressive bull run on its stock that has seen the share price jump from $4.50 to $6.50 at the time of writing.

Prior to that, Humacyte stock had climbed from ~$3 per share to $4.50 per share between mid-April and its earnings announcement - in a little over one month, the stock price is up >110%. The company's market cap valuation at the time of writing is ~$765m....

For further details see: